SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Vogelsang H) "

Sökning: WFRF:(Vogelsang H)

  • Resultat 1-8 av 8
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • VOGELSANG, H, et al. (författare)
  • An ionospheric travelling convection vortex event observed by ground‐based magnetometers and by Viking
  • 1993
  • Ingår i: Geophysical Research Letters. - : American Geophysical Union (AGU). - 0094-8276 .- 1944-8007. ; 20:21, s. 2343-2346
  • Tidskriftsartikel (refereegranskat)abstract
    • A transient ionospheric travelling convection vortex (ITCV) event was recorded by the EISCAT magnetometer cross in northern Scandinavia on April 21, 1986 around 8:40 MLT. Simultaneously, the near-conjugate satellite VIKING observed strong magnetic and electric field variations on closed magnetic field lines. The signatures seen by the spacecraft are consistent with a passage through two oppositely directed field-aligned current tubes. The total upward and downward currents turned out to be matched within a region of approximately 1000 km in the ionosphere. Because of the close spatial and temporal proximity of both observations we interpret the field-aligned currents as being associated with the ITCV. This is the first time that in-situ measurements of the currents connecting the ITCV to the source region close to the magnetopause have been published. Both the current density and the dimensions of the current tubes could be estimated here.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  • de Boer, NKH, et al. (författare)
  • 6-thioguanine treatment in inflammatory bowel disease : A critical appraisal by a European 6-TG working party
  • 2006
  • Ingår i: Digestion. - : S. Karger AG. - 0012-2823 .- 1421-9867. ; 73:1, s. 25-31
  • Tidskriftsartikel (refereegranskat)abstract
    • Recently, the suggestion to use 6-thioguanine (6-TG) as an alternative thiopurine in patients with inflammatory bowel disease (IBD) has been discarded due to reports about possible (hepato) toxicity. During meetings arranged in Vienna and Prague in 2004, European experts applying 6-TG further on in IBD patients presented data on safety and efficacy of 6-TG. After thorough evaluation of its risk-benefit ratio, the group consented that 6-TG may still be considered as a rescue drug in stringently defined indications in IBD, albeit restricted to a clinical research setting. As a potential indication for administering 6-TG, we delineated the requirement for maintenance therapy as well as intolerance and/or resistance to aminosalicylates, azathioprine, 6-mercaptopurine, methotrexate and infliximab. Furthermore, indications are preferred in which surgery is thought to be inappropriate. The standard 6-TG dosage should not exceed 25 mg daily. Routine laboratory controls are mandatory in short intervals. Liver biopsies should be performed after 6-12 months, three years and then three-yearly accompanied by gastroduodenoscopy, to monitor for potential hepatotoxicity, including nodular regenerative hyperplasia (NRH) and veno-occlusive disease (VOD). Treatment with 6-TG must be discontinued in case of overt or histologically proven hepatotoxicity. Copyright (c) 2006 S. Karger AG, Basel.
  •  
6.
  •  
7.
  •  
8.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-8 av 8

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy